Coner

Coner Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for serious ophthalmic diseases, particularly retinal degenerations. The company's lead program, C-001, is a first-in-class oral small molecule currently in Phase 2 clinical trials for the treatment of Geographic Atrophy secondary to dry age-related macular degeneration. Unlike many existing treatments that require frequent intravitreal injections, Coner's approach emphasizes patient-friendly oral administration to improve compliance and long-term outcomes. The company leverages its deep expertise in the visual cycle and retinal biology to advance a pipeline of candidates for conditions like Stargardt disease. Headquartered in Suzhou, China, Coner is backed by prominent investors including Qiming Venture Partners and Eight Roads.